Sanofi: FDA approves asthma drug
(CercleFinance.com) - Sanofi reports that the US FDA has approved Dupixent (dupilumab) for the adjunct treatment of moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma in children aged 6 to 11.
Asthma is one of the most common illnesses in children. About 75,000 children between the ages of six and 11 have moderate-to-severe uncontrolled asthma in the United States, as do many more children elsewhere in the world.
FDA approval was based on data from a phase III trial that evaluated the efficacy and safety of Dupixent, in combination with standard asthma therapy, in children with moderate-to-severe uncontrolled asthma.
Copyright (c) 2021 CercleFinance.com. All rights reserved.